VAY736
Monoclonal antibody
Evidence outlook · registrational
Sjögren's Disease: registrational readout pending
Its supporting mid-stage studies have completed. Registrational readout expected around 2029-08-15.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (12)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (14)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Sjögren's Disease: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| VAY736: this drug | Phase 3 | Monoclonal antibody | — | not yet graded | No reviewed efficacy summary in this indication | |
| Deucravacitinib (Sotyktu) | Phase 3 | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication | |
| Telitacicept | Phase 3 | Protein / enzyme therapeutic | BAFF / APRIL | Partial signal | NCT05673993: Primary endpoint, ESSDAI change at week 24 vs placebo: met; the release gives no figures (RemeGen, 2025-08-13). | |
| Imeroprubart | Phase 2 | Monoclonal antibody | FcRn | not yet graded | No reviewed efficacy summary in this indication | |
| MRT-6160 | Phase 2 | Small molecule | VAV1 | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-319 | Phase 1 | Antibody–drug conjugate | CD19 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(10 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow VAY736 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (4)
March 2027 (1)
What to watch
April 2027 (1)
What to watch
July 2027 (1)
What to watch
September 2027 (1)
What to watch
2029 (2)
2033 (2)
2034 (1)
April 2034 (1)
What to watch
2035 (1)
August 2035 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent